{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:35:32Z","timestamp":1791653732358,"version":"4.3.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study was to review the characteristics, efficacy, and safety of zuranolone in the management of postpartum depression (PPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>Literature was identified using PubMed (1966-August 2023) and EMBASE (1973-August 2023) and clinicaltrials.gov. Search terms included zuranolone, SAGE-217, and PPD with further limitation of those published in English.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Articles selected for inclusion included trials evaluating zuranolone for the treatment of PPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>Zuranolone was evaluated for the treatment of moderate to severe PPD in 2 phase III trials. Both studies resulted in statistically significant improvement in depressive symptoms at day 15 ( P = 0.003 and P &lt; 0.001). Sustained differences in remission rates favoring zuranolone were found in both studies at day 45 compared with placebo ( P = 0.01 and P &lt; 0.05). Zuranolone was well tolerated, with somnolence, dizziness, headache, and sedation reported as the most common side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison to existing drugs:<\/jats:title>\n                    <jats:p>Zuranolone is only the second medication approved by the Food and Drug Administration (FDA) for PPD and offers an advantage over brexanolone in that it can administered orally in the outpatient setting. The rapid onset of effect of zuranolone is advantageous to traditional antidepressant therapy which can be weeks to months; however, limited information is available on safety during lactation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The recent FDA approval of oral zuranolone for PPD offers a second rapid-acting treatment for PPD, extending the opportunity for treatment to patients in the outpatient setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231204953","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:52:55Z","timestamp":1698195175000},"page":"728-734","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-5164","authenticated-orcid":false,"given":"Kylie N.","family":"Barnes","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice and Administration, School of Pharmacy, University of Missouri\u2013Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M.","family":"Vogl","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Missouri\u2013Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-8682","authenticated-orcid":false,"given":"Leigh Anne","family":"Nelson","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administration, School of Pharmacy, University of Missouri\u2013Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"bibr1-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005200"},{"key":"bibr2-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005202"},{"key":"bibr3-10600280231204953","unstructured":"Mughal S, Azhar Y, Siddiqui W. Postpartum depression. Published 2022. Accessed August 18, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519070\/"},{"key":"bibr4-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002295"},{"key":"bibr5-10600280231204953","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15r10174"},{"key":"bibr6-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559"},{"key":"bibr7-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041217-011106"},{"key":"bibr8-10600280231204953","unstructured":"American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. American Psychiatric Association; 2010. Accessed August 30, 2023. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"key":"bibr9-10600280231204953","unstructured":"US Food and Drug Administration. FDA approves first treatment for post-partum depression. Date unknown. Accessed August 24, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-post-partum-depression"},{"key":"bibr10-10600280231204953","unstructured":"US Food and Drug Administration. FDA approves first oral treatment for postpartum depression. Date unknown. Accessed August 24, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-treatment-postpartum-depression"},{"key":"bibr11-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1176\/appi\/ajp.20220785"},{"key":"bibr12-10600280231204953","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14475"},{"key":"bibr13-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333"},{"key":"bibr14-10600280231204953","unstructured":"Zurzuvae (zuranolone) [package insert]. Biogen Inc; 2023."},{"key":"bibr15-10600280231204953","unstructured":"Zulresso (brexanolone) [package insert]. Sage Therapeutics, Inc; 2019."},{"key":"bibr16-10600280231204953","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqv043"},{"key":"bibr17-10600280231204953","unstructured":"Drugs and Lactation Database (LactMed). Zuranolone. Published 2006. Accessed September 15, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594292\/"},{"key":"bibr18-10600280231204953","unstructured":"Clinical Trials Arena. Zuranolone approved for postpartum depression but misses out on bigger MDD indication. Published 2023. Accessed September 15, 2023. https:\/\/www.clinicaltrialsarena.com\/comment\/zuranolone-postpartum-depression-misses-out-mdd-indication\/?cf-view"},{"key":"bibr19-10600280231204953","unstructured":"Drugs.com. Zulresso prices, coupons and patient assistance programs. Date unknown. Accessed August 28, 2023. https:\/\/www.drugs.com\/price-guide\/zulresso"},{"key":"bibr20-10600280231204953","unstructured":"Drugs.com. Sertraline prices, coupons and patient assistance programs. Date unknown. Accessed August 28, 2023. https:\/\/www.drugs.com\/price-guide\/sertraline"},{"key":"bibr21-10600280231204953","unstructured":"Drugs.com. Prozac prices, coupons and patient assistance programs. Date unknown. Accessed August 28, 2023. https:\/\/www.drugs.com\/price-guide\/prozac"},{"key":"bibr22-10600280231204953","unstructured":"Drugs.com. Escitalopram prices, coupons and patient assistance programs. Date unknown. Accessed August 28, 2023. https:\/\/www.drugs.com\/price-guide\/escitalopram"},{"key":"bibr23-10600280231204953","unstructured":"CNN Health. Drugmakers say they\u2019re adjusting their \u201cthinking on price\u201d of first postpartum depression pill approved in the US. Published 2023. Accessed August 28, 2023. https:\/\/www.cnn.com\/2023\/08\/08\/health\/zuranolone-pricing-postpartum-depression\/index.html"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231204953","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231204953","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231204953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:23Z","timestamp":1777374803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231204953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/10600280231204953"],"URL":"https:\/\/doi.org\/10.1177\/10600280231204953","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}